Seres therapeutics announces completion of rolling bla submission to fda for investigational microbiome therapeutic ser-109 for recurrent c. difficile infection

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced it has completed the rolling submission process for its biologics license application (bla) to the u.s. food and drug administration (fda) for ser-109 for the prevention of recurrent c. difficile infection (rcdi). ser-109 is an entirely new treatment modality that shows promise to improve the current standard of care for rcdi. “completing this bla submission mar
MCRB Ratings Summary
MCRB Quant Ranking